



Arthritis Medications Report Card

How does your province measure up?

The JointHealth™ Arthritis Medications Report Card is designed to help Canadians evaluate how their province measures up in terms of providing reimbursement access to medications approved for autoimmune (like rheumatoid arthritis) arthritis treatment.

Depending on where they live, Canadians living with an autoimmune arthritis may have fewer treatment options or have to “jump through more hoops” to qualify for reimbursement for the medication prescribed for them by their rheumatologist or other specialist.

The JointHealth™ Arthritis Medications Report Card highlights this inequality of treatment and now tracks three classes of medications used to treat auto-immune forms of arthritis: **Biologic Response Modifiers (Biologics)**, **subsequent entry biologics (SEBs)** and **Targeted small molecule medications (TSMMs)**.

If your province doesn't measure up, ACE encourages you to write and speak to your elected provincial or federal representative about the lack of equitable reimbursement access and patient/physician choice in treating auto-immune forms of arthritis.

Medications Chart : Updated October 2017

1st : Ontario (Last year: 3rd)

Generic Name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis	non-radiographic axial spondyloarthritis (not visible on X-ray)					
abatacept (Orencia®)	Listed—CBC	N/A	N/A	Listed—CBC	In Trials	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
anakinra (Kineret®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A	N/A	N/A	N/A	Declined	N/A	N/A
canakinumab (Ilaris®)	N/A	N/A	N/A	Under Review	N/A	N/A	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®, boDMARD)	Listed—ORC	Listed—ORC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
etanercept (Brenzys®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A
etanercept (Erelzi®, bsDMARD)	Under Review	Under Review	N/A	Under Review	N/A	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC	Under Review	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®, boDMARD)	Listed—ORC	Listed—ORC	N/A	Listed—CBC	Listed—ORC	N/A	N/A	N/A
infliximab (Inflectra®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
rituximab (Rituxan®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Listed—CBC	N/A
sarilumab (Kevzara®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
secukinumab (Cosentyx®)	N/A	Under Review	N/A	N/A	Under Review	N/A	N/A	N/A

tocilizumab (Actemra®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A	N/A
ustekinumab (Stelara®)	N/A	N/A	N/A	N/A	Declined	N/A	N/A	N/A
apremilast (Otezla®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
tofacitinib citrate (Xeljanz®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A

2nd : Saskatchewan (Last year: 4th)

Generic Name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis	non-radiographic axial spondyloarthritis (not visible on X-ray)					
abatacept (Orencia®)	Listed—CBC	N/A	N/A	Listed—CBC	In Trials	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
anakinra (Kineret®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A	N/A	N/A	N/A	Declined	N/A	N/A
canakinumab (Ilaris®)	N/A	N/A	N/A	Declined	N/A	N/A	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®, boDMARD)	Listed—ORC	Listed—ORC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
etanercept (Brenzys®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A
etanercept (Erelzi®, bsDMARD)	Under Review	Under Review	N/A	Under Review	N/A	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC	Under Review	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®, boDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Inflectra®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
rituximab (Rituxan®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Listed—CBC	N/A
sarilumab (Kevzara®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
secukinumab (Cosentyx®)	N/A	Under Review	N/A	N/A	Under Review	N/A	N/A	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A	N/A
ustekinumab (Stelara®)	N/A	N/A	N/A	N/A	Listed—CBC	N/A	N/A	N/A
apremilast (Otezla®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
tofacitinib citrate (Xeljanz®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A

3rd : Québec (Last year: 1st)

Generic Name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis	non-radiographic axial spondyloarthritis (not visible on X-ray)					
abatacept (Orencia®)	Listed—CBC	N/A	N/A	Listed—CBC	In Trials	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
anakinra (Kineret®)	Declined	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A	N/A	N/A	N/A	Declined	N/A	N/A
canakinumab (Ilaris®)	N/A	N/A	N/A	Under Review	N/A	N/A	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®, boDMARD)	Listed—ORC	Listed—ORC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
etanercept (Brenzys®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A
etanercept (Erelzi®, bsDMARD)	Under Review	Under Review	N/A	Under Review	N/A	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC	Under Review	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®, boDMARD)	Listed—ORC	Listed—ORC	N/A	Listed—CBC	Listed—ORC	N/A	N/A	N/A
infliximab (Inflectra®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
rituximab (Rituxan®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
sarilumab (Kevzara®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
secukinumab (Cosentyx®)	N/A	Declined	N/A	N/A	Declined	N/A	N/A	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A	N/A
ustekinumab (Stelara®)	N/A	N/A	N/A	N/A	Listed—CBC	N/A	N/A	N/A
apremilast (Otezla®)	N/A	N/A	N/A	N/A	Declined	N/A	N/A	N/A
tofacitinib citrate (Xeljanz®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A

4th : Alberta (Last year :7th)

Generic Name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis	non-radiographic axial spondyloarthritis (not visible on X-ray)					
abatacept (Orencia®)	Listed—CBC	N/A	N/A	Listed—ORC	In Trials	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
anakinra (Kineret®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A	N/A	N/A	N/A	Declined	N/A	N/A
canakinumab (Ilaris®)	N/A	N/A	N/A	Declined	N/A	N/A	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®, boDMARD)	Listed—ORC	Listed—ORC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
etanercept (Brenzys®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A
etanercept (Erelzi®, bsDMARD)	Under Review	Under Review	N/A	Under Review	N/A	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC	Under Review	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®, boDMARD)	Listed—ORC	Listed—ORC	N/A	N/A	Listed—ORC	N/A	N/A	N/A
infliximab (Inflectra®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
rituximab (Rituxan®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Listed—CBC	N/A
sarilumab (Kevzara®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
secukinumab (Cosentyx®)	N/A	Under Review	N/A	N/A	Under Review	N/A	N/A	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A	N/A
ustekinumab (Stelara®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
apremilast (Otezla®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
tofacitinib citrate (Xeljanz®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A

5th : British Columbia (Last year: 2nd)

Generic Name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis	non-radiographic axial spondyloarthritis (not visible on X-ray)					
abatacept (Orencia®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
anakinra (Kineret®)	Declined	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A	N/A	N/A	N/A	Declined	N/A	N/A
canakinumab (Ilaris®)	N/A	N/A	N/A	Declined	N/A	N/A	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®, boDMARD)	Listed—ORC	Listed—ORC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
etanercept (Brenzys®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A
etanercept (Erelzi®, bsDMARD)	Under Review	Under Review	N/A	Under Review	N/A	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC	Under Review	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®, boDMARD)	Listed—ORC	Listed—ORC	N/A	N/A	Listed—ORC	N/A	N/A	N/A
infliximab (Inflectra®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
rituximab (Rituxan®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Listed—CBC	N/A
sarilumab (Kevzara®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
secukinumab (Cosentyx®)	N/A	Under Review	N/A	N/A	Under Review	N/A	N/A	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A	N/A
ustekinumab (Stelara®)	N/A	N/A	N/A	N/A	Declined	N/A	N/A	N/A
apremilast (Otezla®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
tofacitinib citrate (Xeljanz®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A

6th : Manitoba (Last year: 8th)

Generic Name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis	non-radiographic axial spondyloarthritis (not visible on X-ray)					
abatacept (Orencia®)	Listed—CBC	N/A	N/A	Under Review	In Trials	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
anakinra (Kineret®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A	N/A	N/A	N/A	Under Review	N/A	N/A
canakinumab (Ilaris®)	N/A	N/A	N/A	Under Review	N/A	N/A	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®, boDMARD)	Listed—ORC	Listed—ORC	N/A	Unknown	Listed—CBC	N/A	N/A	N/A
etanercept (Brenzys®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A
etanercept (Erelzi®, bsDMARD)	Under Review	Under Review	N/A	Under Review	N/A	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC	Under Review	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®, boDMARD)	Listed—ORC	Listed—ORC	N/A	N/A	Listed—ORC	N/A	N/A	N/A
infliximab (Inflectra®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
rituximab (Rituxan®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Listed—CBC	N/A
sarilumab (Kevzara®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
secukinumab (Cosentyx®)	N/A	Under Review	N/A	N/A	Under Review	N/A	N/A	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A	N/A
ustekinumab (Stelara®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
apremilast (Otezla®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
tofacitinib citrate (Xeljanz®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A

6th : Prince Edward Island (Last year: 6th)

Generic Name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis	non-radiographic axial spondyloarthritis (not visible on X-ray)					
abatacept (Orencia®)	Listed—CBC	N/A	N/A	Listed—CBC	In Trials	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
anakinra (Kineret®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A	N/A	N/A	N/A	Under Review	N/A	N/A
canakinumab (Ilaris®)	N/A	N/A	N/A	Under Review	N/A	N/A	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®, boDMARD)	Listed—ORC	Listed—ORC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
etanercept (Brenzys®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A
etanercept (Erelzi®, bsDMARD)	Under Review	Under Review	N/A	Under Review	N/A	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC	Under Review	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®, boDMARD)	Listed—ORC	Listed—ORC	N/A	N/A	Listed—ORC	N/A	N/A	N/A
infliximab (Inflectra®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
rituximab (Rituxan®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Listed—CBC	N/A
sarilumab (Kevzara®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
secukinumab (Cosentyx®)	N/A	Under Review	N/A	N/A	Under Review	N/A	N/A	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A	N/A
ustekinumab (Stelara®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
apremilast (Otezla®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
tofacitinib citrate (Xeljanz®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A

8th : Nova Scotia (Last year: 4th)

Generic Name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis	non-radiographic axial spondyloarthritis (not visible on X-ray)					
abatacept (Orencia®)	Listed—CBC	N/A	N/A	Listed—CBC	In Trials	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
anakinra (Kineret®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A	N/A	N/A	N/A	Under Review	N/A	N/A
canakinumab (Ilaris®)	N/A	N/A	N/A	Under Review	N/A	N/A	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®, boDMARD)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
etanercept (Brenzys®, bsDMARD)	Under Review	Under Review	N/A	N/A	N/A	N/A	N/A	N/A
etanercept (Erelzi®, bsDMARD)	Under Review	Under Review	N/A	Under Review	N/A	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC	Under Review	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®, boDMARD)	Listed—ORC	Listed—ORC	N/A	N/A	Listed—ORC	N/A	N/A	N/A
infliximab (Inflectra®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
rituximab (Rituxan®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Listed—CBC	N/A
sarilumab (Kevzara®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
secukinumab (Cosentyx®)	N/A	Under Review	N/A	N/A	Under Review	N/A	N/A	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A	N/A
ustekinumab (Stelara®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
apremilast (Otezla®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
tofacitinib citrate (Xeljanz®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A

8th : New Brunswick (Last year: 8th)

Generic Name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis	non-radiographic axial spondyloarthritis (not visible on X-ray)					
abatacept (Orencia®)	Listed—CBC	N/A	N/A	Listed—CBC	In Trials	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
anakinra (Kineret®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A	N/A	N/A	N/A	Declined	N/A	N/A
canakinumab (Ilaris®)	N/A	N/A	N/A	Declined	N/A	N/A	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®, boDMARD)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
etanercept (Brenzys®, bsDMARD)	Under Review	Under Review	N/A	N/A	N/A	N/A	N/A	N/A
etanercept (Erelzi®, bsDMARD)	Under Review	Under Review	N/A	Under Review	N/A	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC	Under Review	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®, boDMARD)	Listed—ORC	Listed—ORC	N/A	N/A	Listed—ORC	N/A	N/A	N/A
infliximab (Inflectra®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
rituximab (Rituxan®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Listed—CBC	N/A
sarilumab (Kevzara®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
secukinumab (Cosentyx®)	N/A	Under Review	N/A	N/A	Under Review	N/A	N/A	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A	N/A
ustekinumab (Stelara®)	N/A	N/A	N/A	N/A	Declined	N/A	N/A	N/A
apremilast (Otezla®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
tofacitinib citrate (Xeljanz®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A

10th : Newfoundland and Labrador (Last year: 10th)

Generic Name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis	non-radiographic axial spondyloarthritis (not visible on X-ray)					
abatacept (Orencia®)	Listed—CBC	N/A	N/A	Listed—CBC	In Trials	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
anakinra (Kineret®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A	N/A	N/A	N/A	Under Review	N/A	N/A
canakinumab (Ilaris®)	N/A	N/A	N/A	Under Review	N/A	N/A	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®, boDMARD)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
etanercept (Brenzys®, bsDMARD)	Under Review	Under Review	N/A	N/A	N/A	N/A	N/A	N/A
etanercept (Erelzi®, bsDMARD)	Under Review	Under Review	N/A	Under Review	N/A	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC	Under Review	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®, boDMARD)	Listed—ORC	Listed—ORC	N/A	N/A	Declined	N/A	N/A	N/A
infliximab (Inflectra®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
rituximab (Rituxan®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Listed—CBC	N/A
sarilumab (Kevzara®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
secukinumab (Cosentyx®)	N/A	Under Review	N/A	N/A	Under Review	N/A	N/A	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A	N/A
ustekinumab (Stelara®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
apremilast (Otezla®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
tofacitinib citrate (Xeljanz®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A

11th : NIHB* (Last year: 11th)

Generic Name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis	non-radiographic axial spondyloarthritis (not visible on X-ray)					
abatacept (Orencia®)	Listed—CBC	N/A	N/A	Listed—CBC	In Trials	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
anakinra (Kineret®)	Declined	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A	N/A	N/A	N/A	Under Review	N/A	N/A
canakinumab (Ilaris®)	N/A	N/A	N/A	Under Review	N/A	N/A	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®, boDMARD)	Listed—CBC	Listed—CBC	N/A	Listed—CBC	Listed—CBC	N/A	N/A	N/A
etanercept (Brenzys®, bsDMARD)	Under Review	Under Review	N/A	N/A	N/A	N/A	N/A	N/A
etanercept (Erelzi®, bsDMARD)	Under Review	Under Review	N/A	Under Review	N/A	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC	Under Review	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®, boDMARD)	Listed—ORC	Declined	N/A	N/A	Declined	N/A	N/A	N/A
infliximab (Inflectra®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
rituximab (Rituxan®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
sarilumab (Kevzara®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
secukinumab (Cosentyx®)	N/A	Under Review	N/A	N/A	Under Review	N/A	N/A	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A	N/A
ustekinumab (Stelara®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
apremilast (Otezla®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
tofacitinib citrate (Xeljanz®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A

12th : Yukon (Last year: 12th)

Generic Name (Brand Name)	rheumatoid arthritis	axial spondyloarthritis		juvenile idiopathic arthritis	psoriatic arthritis	systemic lupus erythematosus	vasculitis	osteoporosis
		ankylosing spondylitis	non-radiographic axial spondyloarthritis (not visible on X-ray)					
abatacept (Orencia®)	Under Review	N/A	N/A	Under Review	In Trials	N/A	N/A	N/A
adalimumab (Humira®)	Listed—CBC	Listed—CBC	N/A	Under Review	Listed—CBC	N/A	N/A	N/A
anakinra (Kineret®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A
belimumab (Benlysta®)	N/A	N/A	N/A	N/A	N/A	Under Review	N/A	N/A
canakinumab (Ilaris®)	N/A	N/A	N/A	Under Review	N/A	N/A	N/A	N/A
certolizumab pegol (Cimzia®)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
denosumab (Prolia®)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Listed—CBC
etanercept (Enbrel®, boDMARD)	Listed—ORC	Listed—ORC	N/A	Under Review	Listed—CBC	N/A	N/A	N/A
etanercept (Brenzys®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A
etanercept (Erelzi®, bsDMARD)	Under Review	Under Review	N/A	Under Review	N/A	N/A	N/A	N/A
golimumab (Simponi®)	Listed—CBC	Listed—CBC	Under Review	N/A	Listed—CBC	N/A	N/A	N/A
infliximab (Remicade®, boDMARD)	Listed—ORC	Listed—ORC	N/A	N/A	Listed—ORC	N/A	N/A	N/A
infliximab (Inflectra®, bsDMARD)	Listed—CBC	Listed—CBC	N/A	N/A	Listed—CBC	N/A	N/A	N/A
rituximab (Rituxan®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	Under Review	N/A
sarilumab (Kevzara®)	Under Review	N/A	N/A	N/A	N/A	N/A	N/A	N/A
secukinumab (Cosentyx®)	N/A	Under Review	N/A	N/A	Under Review	N/A	N/A	N/A
tocilizumab (Actemra®)	Listed—CBC	N/A	N/A	Under Review	N/A	N/A	N/A	N/A
ustekinumab (Stelara®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
apremilast (Otezla®)	N/A	N/A	N/A	N/A	Under Review	N/A	N/A	N/A
tofacitinib citrate (Xeljanz®)	Listed—CBC	N/A	N/A	N/A	N/A	N/A	N/A	N/A

About the report card:

Arthritis Consumer Experts graded each of the provinces by assigning a score based upon number of medications listed, number under review, and number of declined listings. In some cases, information was unavailable from a province or territory's website. This lack of transparency was reflected in grade assignments.

Because provincial formularies change frequently, we encourage you to contact the Ministry of Health in your province with questions you may have about medication listings of concern to you.

Definitions

Declined: The formulary does not reimburse patients prescribed this medication.

In Trials: This medication is undergoing testing for use in treating this disease type.

Listed—CBC: Each province and territory has a process by which medications that are not normally included in the provincial, territorial or federal drug benefit lists are covered (or reimbursed). Approval of this drug is granted on a case-by-case basis.

Listed—ORC: The medication is listed, but the criteria are not supported by medical evidence. Arthritis Consumer Experts considers these overly restrictive criteria (ORC) unacceptable.

N/A: (Not Applicable) No Notice of Compliance (or NOC) has been issued for this medication for this form of arthritis.

Under Review: This drug has been approved by Health Canada for this disease type and the province is considering whether patients should be reimbursed for it.

Unknown: There is no public information available.

CDR: The Common Drug Review (CDR) is part of the Canadian Agency for Drugs and Technologies in Health. The Common Drug Review (CDR) conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Québec). (<http://cadth.ca/index.php//cdr>)

* **Note:** People living in the Northwest Territories and Nunavut, who do not have private health insurance, have coverage for those drugs listed on the federal Non-Insured Health Benefits (NIHB) Formulary.

Disclaimer: The material contained in this or any other ACE publication is provided for general information only. It should not be relied on to suggest a course of treatment for a particular individual or as a substitute for consultation with qualified health professionals who are familiar with your individual medical needs. If you have any healthcare related questions or concerns, you should contact your physician. Never disregard medical advice or delay in seeking it because of something you have read in any ACE publication.